Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as a lyophilized powder for solution for injection for intravenous and subcutaneous use. It is used to treat neutropenia associated with chemotherapy, bone‑marrow transplantation, severe chronic neutropenia, aplastic anemia and to mobilise peripheral blood progenitor cells.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) acts on the hematopoietic system to stimulate neutrophil production and is indicated for several neutropenic conditions. - Neutropenia associated with chemotherapy: shortens the duration of severe neutropenia and reduces infection risk. - Bone marrow transplantation: supports engraftment by enhancing neutrophil recovery. - Severe chronic neutropenia: increases absolute neutrophil count and improves clinical outcomes. - Aplastic anemia: aids hematopoietic recovery when used as adjunct therapy. - Peripheral blood progenitor cell mobilization: facilitates collection of stem cells for autologous transplantation.

Neupogen is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Bone pain: mild to moderate discomfort, often in the limbs. - Injection site reactions: redness, swelling, or itching. - Fever: transient low‑grade elevations. - Headache: mild and self‑limiting. - Nausea: occasional mild gastrointestinal upset.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening. - Acute respiratory distress syndrome (ARDS): very uncommon. - Allergic reactions: including anaphylaxis, rash, or angioedema. - Leukocytosis: excessive white‑blood‑cell counts. - Capillary leak syndrome: rare fluid accumulation. - Myelodysplastic syndrome: extremely rare transformation.

Before initiating therapy, clinicians should consider several safety measures. - Dose adjustment: evaluate renal and hepatic function, especially in elderly patients. - Monitor blood counts: perform regular complete blood count (CBC) assessments. - Avoid in hypersensitivity: discontinue if signs of allergic reaction appear. - Caution with splenomegaly: assess spleen size and monitor for abdominal pain. - Pregnancy and lactation: safety unknown; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other agents that affect the immune system or hematopoiesis.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may diminish filgrastim efficacy. - Live vaccines: increased risk of infection due to altered immune response.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may reduce neutrophil response. - Broad‑spectrum antibiotics: can mask signs of infection. - Other hematopoietic growth factors: overlapping mechanisms may increase adverse event risk.